Evidence map›Paper›PMID 30880361›Full record

ReviewCurrent psychiatry reports2019

Advances in the Treatment of Tourette's Disorder.

Madeline A Chadehumbe, Lawrence W Brown

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current psychiatry reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Madeline A ChadehumbeDivision of Neurology, Children's Hospital of Philadelphia, The University of Pennsylvania Perelman School of Medicine, 3501 Civic Center Boulevard, Philadelphia, PA, USA. chadehumbm@email.chop.edu.
Lawrence W BrownDivision of Neurology, Children's Hospital of Philadelphia, The University of Pennsylvania Perelman School of Medicine, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis article was written in order to bring the reader up to date with developments that have occurred in the treatment of Tourette disorder (TD) over the last 5 years. RECENT

findingsDespite the fact that TD has been recognized for over a century, the understanding of the underlying mechanisms remains poor. There has been limited development in the last 5 years for new therapeutic options. Aripipazole is the only newly approved pharmaceutical therapy for TD in the last 5 years, although several medications are under active study. For the most severely affected individuals, there is increasing experience with surgical interventions. One of the most promising areas of research is the work of genetic consortiums currently looking into identifying the underlying pathogenetic basis which in turn will hopefully lead to the development of safer and more effective therapies.

Indexed as

AripiprazoleBehavior TherapyDopamine D2 Receptor AntagonistsGenetic TherapyHumansTourette SyndromeAripiprazoleDopamine D2 Receptor AntagonistsCurrentTherapyTouretteTreatment

Identifiers

PMID30880361
OpenAlexW2922304119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.